SCHEMBL611896

SCHEMBL611896

CC(C)(C)C(CCO)C(=O)O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CA2 P00918 1/20 0.33
MAPK1 P28482 1/20 0.33
HSPD1 P10809 1/20 0.32
BLM P54132 1/20 0.32
HSPE1 P61604 1/20 0.32
GABRP O00591 2/20 0.31
GABRD O14764 2/20 0.31
GABRA1 P14867 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29061427 0.84 HSPD1 (0.40) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL3988978 0.82 HSPD1 (0.42) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL1966037 0.80 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL17231916 0.80 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL667279 0.79 OR51E2 (0.39) CHRM1ADRA1AALDH1A1MAPTPTGS1
SCHEMBL13316605 0.79 OR51E2 (0.39) CHRM1ADRA1AALDH1A1MAPTPTGS1
SCHEMBL10915204 0.78 CA2 (0.32) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL3189905 0.78 ALDH1A1 (0.33) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL18120593 0.78 GRN (0.37) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL22091806 0.78 CA2 (0.32) CHRM1AKR1A1CHRM3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140256831-A1 HYDROGEL AND METHOD FOR PRODUCING SAME THE UNIVERSITY OF TOKYO (JP) 2014-09-11 US disclosed
US-20120041019-A1 PROTEASE INHIBITORS AMPLYX PHARMACEUTICALS, INC. 2012-02-16 US disclosed
WO-2010077317-A2 PROTEASE INHIBITORS AMPLYX PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed
US-5830936-A THERMAL STABILIZERS FOR POLYOLEFINS AND ENGINEERING PLASTICS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256831-A1 HYDROGEL AND METHOD FOR PRODUCING SAME CD44, CSGALNACT1, CDC37 CHRM1 2133/4885AKR1A1 4043/4885CHRM3 1940/4885
US-20120041019-A1 PROTEASE INHIBITORS SERPINB1, PREP, DNPEP CHRM1 4808/4885AKR1A1 2821/4885CHRM3 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.